Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$146.60 USD
-4.66 (-3.08%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $146.48 -0.12 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ASND 146.60 -4.66(-3.08%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Other News for ASND
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary
RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Ascendis Pharma prices $300M equity offering
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs